PODD - Insulet Corporation
NASDAQ
->
Healthcare
->
Medical Devices
Acton,
United States
Type: Equity
PODD price evolution
PODD
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $704.2 | $685.4 | $660.1 | $620.7 |
| Short term investments | ||||
| Net receivables | $359.7 | $270.3 | $250.5 | $217.2 |
| Inventory | $402.6 | $410.8 | $411.3 | $386.1 |
| Total current assets | $1582.9 | $1471.1 | $1421.5 | $1330 |
| Long term investments | ||||
| Property, plant & equipment | $664.9 | $649.2 | $601.5 | $596.6 |
| Goodwill & intangible assets | $150.4 | $151.2 | $151.2 | $151.9 |
| Total noncurrent assets | $1005.3 | $996.6 | $964.3 | $959.1 |
| Total investments | ||||
| Total assets | $2588.2 | $2467.7 | $2385.8 | $2289.1 |
| Current liabilities | ||||
| Accounts payable | $19.2 | $77.8 | $107.5 | $85.9 |
| Deferred revenue | ||||
| Short long term debt | $49.4 | $49.8 | $29.2 | $27.8 |
| Total current liabilities | $451.2 | $451.4 | $425 | $383.3 |
| Long term debt | $1366.4 | $1370.6 | $1368.6 | $1368.8 |
| Total noncurrent liabilities | $1404.3 | $1408.8 | $1406.9 | $1403 |
| Total debt | $1415.8 | $1420.4 | $1397.8 | $1396.6 |
| Total liabilities | $1855.5 | $1860.2 | $1831.9 | $1786.3 |
| Shareholders' equity | ||||
| Retained earnings | -$378 | -$481.3 | -$533.2 | -$560.5 |
| Other shareholder equity | $8 | $7.6 | $16.3 | $15.9 |
| Total shareholder equity | $732.7 | $607.5 | $553.9 | $502.8 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $704.2 | $136.1 | $791.6 | $907.2 |
| Short term investments | $40.4 | |||
| Net receivables | $359.7 | $205.6 | $161 | $83.8 |
| Inventory | $402.6 | $346.8 | $303.2 | $154.3 |
| Total current assets | $1582.9 | $1314 | $1329.8 | $1248.7 |
| Long term investments | ||||
| Property, plant & equipment | $664.9 | $625.9 | $536.5 | $478.7 |
| Goodwill & intangible assets | $150.4 | $127.2 | $76.4 | $68.5 |
| Total noncurrent assets | $1005.3 | $937.1 | $719 | $624.2 |
| Total investments | $40.4 | |||
| Total assets | $2588.2 | $2251.1 | $2048.8 | $1872.9 |
| Current liabilities | ||||
| Accounts payable | $19.2 | $30.8 | $198.7 | $54.1 |
| Deferred revenue | ||||
| Short long term debt | $49.4 | $27.5 | $25.1 | $15.6 |
| Total current liabilities | $451.2 | $364.7 | $228.8 | $207.8 |
| Long term debt | $1366.4 | $1374.3 | $1248.8 | $1043.7 |
| Total noncurrent liabilities | $1404.3 | $1410 | $1263.7 | $1061.5 |
| Total debt | $1415.8 | $1401.8 | $1273.9 | $1059.3 |
| Total liabilities | $1855.5 | $1774.7 | $1492.5 | $1269.3 |
| Shareholders' equity | ||||
| Retained earnings | -$378 | -$584.3 | -$649.5 | -$666.3 |
| Other shareholder equity | $8 | -$17 | -$2.2 | $5.5 |
| Total shareholder equity | $732.7 | $476.4 | $556.3 | $603.6 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $509.8 | $432.7 | $396.5 | $358.1 |
| Cost of revenue | $148.6 | $139.4 | $131.6 | $117.6 |
| Gross Profit | $361.2 | $293.3 | $264.9 | $240.5 |
| Operating activities | ||||
| Research & development | $42 | $57.8 | $55.1 | $50.1 |
| Selling, general & administrative | $212.8 | $180.7 | $178.7 | $162.7 |
| Total operating expenses | $254.8 | $238.5 | $233.8 | $212.8 |
| Operating income | $106.4 | $54.8 | $31.1 | $27.7 |
| Income from continuing operations | ||||
| EBIT | $114.5 | $64.1 | $30.9 | $27.5 |
| Income tax expense | $4.5 | $1.8 | $1.2 | $0.8 |
| Interest expense | $6.7 | $10.4 | $2.4 | $2.9 |
| Net income | ||||
| Net income | $103.3 | $51.9 | $27.3 | $23.8 |
| Income (for common shares) | $103.3 | $51.9 | $27.3 | $23.8 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1697.1 | $1305.3 | $1098.8 | $904.4 |
| Cost of revenue | $537.2 | $499.7 | $346.7 | $322.1 |
| Gross Profit | $1159.9 | $805.6 | $752.1 | $582.3 |
| Operating activities | ||||
| Research & development | $205 | $180.2 | $160.1 | $146.8 |
| Selling, general & administrative | $734.9 | $587.8 | $466 | $384 |
| Total operating expenses | $939.9 | $768 | $626.1 | $530.8 |
| Operating income | $220 | $37.6 | $126 | $51.5 |
| Income from continuing operations | ||||
| EBIT | $250.8 | $36.5 | $81.7 | $54.8 |
| Income tax expense | $8.3 | $5.2 | $3.7 | $2.9 |
| Interest expense | $36.2 | $26.7 | $61.2 | $45.1 |
| Net income | ||||
| Net income | $206.3 | $4.6 | $16.8 | $6.8 |
| Income (for common shares) | $206.3 | $4.6 | $16.8 | $6.8 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | $103.3 | $51.9 | $27.3 | $23.8 |
| Operating activities | ||||
| Depreciation | $18.8 | $18.7 | $18.1 | $17.2 |
| Business acquisitions & disposals | -$3 | |||
| Stock-based compensation | $12.6 | $10.5 | $13.1 | $12.1 |
| Total cash flows from operations | $45.2 | $56 | $44 | $0.5 |
| Investing activities | ||||
| Capital expenditures | -$56.7 | -$22.4 | -$18.1 | -$12 |
| Investments | -$0.2 | -$5 | -$2 | |
| Total cash flows from investing | -$31.6 | -$22.6 | -$23.1 | -$42.1 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $9 | $0.1 | $11.8 | $6 |
| Net borrowings | -$7 | -$6.8 | -$6.8 | -$6.7 |
| Total cash flows from financing | $2.2 | -$6.9 | $3.2 | -$12.1 |
| Effect of exchange rate | $3 | -$1.2 | $0.1 | -$0.1 |
| Change in cash and equivalents | $18.8 | $25.3 | $24.2 | -$53.8 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $206.3 | $4.6 | $16.8 | $6.8 |
| Operating activities | ||||
| Depreciation | $72.8 | $63.2 | $57.4 | $55.4 |
| Business acquisitions & disposals | -$3 | -$26 | ||
| Stock-based compensation | $48.3 | $40.9 | $34.4 | $35.9 |
| Total cash flows from operations | $145.7 | $119 | -$68.1 | $84 |
| Investing activities | ||||
| Capital expenditures | -$109.2 | -$135.8 | -$111.9 | -$129 |
| Investments | -$7.2 | -$7.8 | $40 | $180.5 |
| Total cash flows from investing | -$119.4 | -$191.1 | -$82.7 | $14 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $26.9 | $16.3 | $23.5 | $509.2 |
| Net borrowings | -$27.3 | -$39.8 | $45.4 | $128.3 |
| Total cash flows from financing | -$13.6 | -$40.3 | $40.7 | $605.5 |
| Effect of exchange rate | $1.8 | -$4.3 | -$5.5 | $4.8 |
| Change in cash and equivalents | $14.5 | -$116.7 | -$115.6 | $708.3 |
News
|
Will Acute Care Unit Aid Universal Health's (UHS) Q1 Earnings?
Zacks via Yahoo Finance
19 Apr 2024
|
|
3 Weight-Loss ETFs to Profit From the Obesity Drug Boom
InvestorPlace
17 Apr 2024
|
|
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Zacks via Yahoo Finance
16 Apr 2024
|
|
Earnings growth outpaced the impressive 16% CAGR delivered to Insulet (NASDAQ:PODD) shareholders...
Simply Wall St. via Yahoo Finance
15 Apr 2024
|
|
How an unusual partnership in e.l.f. Beauty’s C-suite has contributed to the company’s massive...
Fortune
21 Mar 2024
|
|
3 Strong Stocks Down at Least 30% to Buy Now
Zacks via Yahoo Finance
21 Mar 2024
|
|
10 NASDAQ Stocks with Biggest Upside
Insider Monkey via Yahoo Finance
20 Mar 2024
|
|
Here’s Why Insulet (PODD) Detracted in Q4
Insider Monkey via Yahoo Finance
19 Mar 2024
|
|
Here's Why You Should Buy Insulet (PODD) Stock Right Now
Zacks via Yahoo Finance
18 Mar 2024
|
|
Why Insulet (PODD) is a Top Growth Stock for the Long-Term
Zacks via Yahoo Finance
14 Mar 2024
|
Fundamentals
| Market cap | $11.62B |
|---|---|
| Enterprise value | $12.33B |
| Shares outstanding | 69.91M |
| Revenue | $1.70B |
|---|---|
| EBITDA | $309.80M |
| EBIT | $237.00M |
| Net Income | $206.30M |
| Revenue Q/Q | 37.90% |
| Revenue Y/Y | 30.02% |
| P/E ratio | 56.34 |
|---|---|
| EV/Sales | 7.27 |
| EV/EBITDA | 39.81 |
| EV/EBIT | 52.04 |
| P/S ratio | 6.85 |
| P/B ratio | 16.04 |
| Book/Share | 10.37 |
| Cash/Share | 10.07 |
| EPS | $2.95 |
|---|---|
| ROA | 8.48% |
| ROE | 34.43% |
| Debt/Equity | 2.53 |
|---|---|
| Net debt/EBITDA | 3.72 |
| Current ratio | 3.51 |
| Quick ratio | 2.62 |